Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LYVE1 encodes a type I integral membrane glycoprotein. Additionally we are shipping LYVE1 Proteins (35) and LYVE1 Kits (14) and many more products for this protein.
Showing 10 out of 235 products:
Mouse (Murine) Polyclonal LYVE1 Primary Antibody for EIA, FACS - ABIN115689
Jackson: The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. in Trends in cardiovascular medicine 2003
Show all 7 references for ABIN115689
Human Polyclonal LYVE1 Primary Antibody for EIA, IHC (p) - ABIN357391
Cursiefen, Schlötzer-Schrehardt, Küchle, Sorokin, Breiteneder-Geleff, Alitalo, Jackson: Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. in Investigative ophthalmology & visual science 2002
Show all 5 references for ABIN357391
Human Polyclonal LYVE1 Primary Antibody for EIA, FACS - ABIN115663
Mouta Carreira, Nasser, di Tomaso, Padera, Boucher, Tomarev, Jain: LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. in Cancer research 2001
Show all 4 references for ABIN115663
Mouse (Murine) Monoclonal LYVE1 Primary Antibody for FACS, IHC (p) - ABIN1449242
Hirashima, Sano, Morisada, Murakami, Rossant, Suda: Lymphatic vessel assembly is impaired in Aspp1-deficient mouse embryos. in Developmental biology 2008
Show all 4 references for ABIN1449242
Mouse (Murine) Polyclonal LYVE1 Primary Antibody for EIA, FACS - ABIN126137
Sleeman, Krishnan, Kirkin, Baumann: Markers for the lymphatic endothelium: in search of the holy grail? in Microscopy research and technique 2001
Show all 3 references for ABIN126137
Human Polyclonal LYVE1 Primary Antibody for EIA, IHC (p) - ABIN357392
Cunnick, Jiang, Gomez, Mansel: Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. in Biochemical and biophysical research communications 2001
Show all 3 references for ABIN357392
Human Polyclonal LYVE1 Primary Antibody for IHC (p), WB - ABIN388752
Banerji, Ni, Wang, Clasper, Su, Tammi, Jones, Jackson: LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. in The Journal of cell biology 1999
Show all 2 references for ABIN388752
Human Polyclonal LYVE1 Primary Antibody for WB - ABIN616055
Heindl, Hofmann, Adler, Knorr, Holbach, Naumann, Kruse, Cursiefen: Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension? in Ophthalmology 2010
Show all 2 references for ABIN616055
Cow (Bovine) Polyclonal LYVE1 Primary Antibody for WB - ABIN2782730
Ishikawa, Akishima-Fukasawa, Ito, Akasaka, Yokoo, Ishii: Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. in Cancer 2008
These results demonstrate the prerequisite of a critical LYVE-1 threshold density and show that hyaluronan binding may be elicited in lymphatic endothelium by surface clustering with divalent LYVE-1 mAbs.
We have established a novel, three-protein biomarker panel that is able to detect patients with early-stage pancreatic cancer in urine specimens:LYVE-1, REG1A (show REG1A Antibodies), and TFF1 (show TFF1 Antibodies) were selected as candidate biomarkers
Data (including data from studies in knockout mice) suggest LYVE1 mediates adhesion of group A Streptococci (GAS) to lymphatic vesicular endothelium via capsular hyaluronan; this appears to be critical factor for lymphatic trafficking of GAS in vivo.
High expression of LYVE-1 is associated with atherosclerotic arteries.
Data indicate that detection of lymphatic vascular invasion (LVI) can be optimized by specific D2-40 or LYVE-1 staining.
High-low cell surface HA content of tumor cells through the interaction with LYVE-1 leads to adhesion differences.
FGF2 (show FGF2 Antibodies) binds to LYVE-1 with a higher affinity than any other known LYVE-1-binding molecules, such as hyaluronan or PDGF (show PDGFA Antibodies)-BB. Glycosylation of LYVE-1 is important for FGF2 (show FGF2 Antibodies) binding.
CRSBP-1-associated fibrillar structures are identical to the ER network as evidenced by the co-localization of CRSBP-1 and BiP (show GDF10 Antibodies) in these cells
LYVE-1 may have value as predictor of outcome in neuroblastoma (show ARHGEF16 Antibodies)
Significant correlation between LYVE-1 and Prox-1 (show PROX1 Antibodies) expression was observed in non-small cell lung cancer. Expression was also correlated with lymph node metastasis.
Endogenous hyaluronan on the surface of macrophages can engage LYVE-1, facilitating their adhesion and transit across lymphatic endothelium.
MT1-MMP (show MMP14 Antibodies) directly cleaves LYVE-1 on lymphatic endothelial cells to inhibit LYVE-1-mediated lymphangiogenic responses and restrains the production of VEGF-C (show VEGFC Antibodies).
Data (including data from studies in knockout mice) suggest Lyve1 mediates adhesion of group A Streptococci (GAS) to lymphatic vesicular endothelium via capsular hyaluronan; this appears to be critical factor for lymphatic trafficking of GAS in vivo.
Data show that the expression of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE 1) was similar with vascular endothelial growth factor C (VEGF-C (show VEGFC Antibodies)), but its peak appeared 1-2 d later than that of VEGF-C (show VEGFC Antibodies).
LMW-HA may play a critical role in the processes required for lymphangiogenesis through interactions with its receptor LYVE-1 and triggering intracellular signal cascades.
Studied the specific targeting property of lymphatic vessel endothelial hyaluronan receptor-1 binding polyethylene glycol-coated ultrasmall superparamagnetic iron oxide (LYVE-1-PEG (show PAEP Antibodies)-USPIO) nanoparticles to mouse lymphatic endothelial cells.
Reelin (show RELN Antibodies)-deficient mice showed abnormal collecting lymphatic vessels, characterized by a reduced number of SMCs, abnormal expression of lymphatic capillary marker lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and impaired function
report intact CD31 (show PECAM1 Antibodies)(+) corneal lymphatic capillary endothelial cells that do not express LYVE-1. The number of LYVE-1(-) gaps initially increased until 8 wk of age but was significantly reduced in aged mice.
Adrenomedullin (show ADM Antibodies) and SB431542 enhance the induction of LYVE-1-positive endothelial cells during late phase differentiation.
CRSBP-1 ligands induce disruption of VE-cadherin (show CDH5 Antibodies)-mediated intercellular adhesion and opening of intercellular junctions in lymphatic endothelial cell.
CRSBP-1 plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence.
This gene encodes a type I integral membrane glycoprotein. The encoded protein acts as a receptor and binds to both soluble and immobilized hyaluronan. This protein may function in lymphatic hyaluronan transport and have a role in tumor metastasis.
lymphatic vessel endothelial hyaluronan receptor 1
, extracellular link domain containing 1
, lymphatic endothelial hyaluronan receptor LYVE-1
, lymphatic vessel endothelial hyaluronic acid receptor 1
, cell surface retention sequence binding protein-1
, cell surface retention sequence-binding protein 1
, extracellular link domain-containing 1
, extracellular link domain-containing protein 1
, hyaluronic acid receptor
, extra cellular link domain-containing 1
, lymphatic vessel endothelial HA receptor-1
, lymphatic vessel endothelial HA recptor-1